Opdivo: Clinical Trials

5 trials of Opdivo, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 recruiting. 5 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 45Completed 4, Recruiting 1

Follow Opdivo: new trials by email Literature Review of Opdivo trials Research Report on Opdivo

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Cabozantinib and Nivolumab Among Older Patients With Renal Cell Carcinoma
Nivolumab, Cabozantinib - Kidney Cancer, Renal Cell Cancer
Phase 4RecruitingGustave Roussy, Cancer Campus, Grand Paris502025-05-162025-09-24
A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
Nivolumab, Ipilimumab - Kidney Neoplasms
Phase 4CompletedBristol-Myers Squibb1012020-12-172025-07-11
Study of Nivolumab for Advanced Cancers in India
Nivolumab - Non-Small Cell Lung Cancer (NSCLC), Non-Small-Cell Lung Carcinoma
Phase 4CompletedBristol-Myers Squibb1002018-03-062020-12-04
A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
Nivolumab, Ipilimumab - Renal Cell Carcinoma
Phase 4CompletedBristol-Myers Squibb2112017-01-162022-11-01
An Investigational Immuno-therapy Safety Trial of Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma
Nivolumab - Renal Cell Carcinoma
Phase 4CompletedBristol-Myers Squibb1972016-01-082022-10-27

Conditions studied

Carcinoma, Renal Cell (3)  ·  Kidney Neoplasms (3)  ·  Carcinoma, Non-Small-Cell Lung (1)

Sponsors

Bristol-Myers Squibb (4)  ·  Gustave Roussy, Cancer Campus, Grand Paris (1)

Countries

India (2)  ·  United States (2)  ·  France (1)

Results publications

PMID 35210307, PMID 36104138

NIH funding

2015 (1)